Chardan raised the firm’s price target on Silence Therapeutics to $42 from $26 and keeps a Buy rating on the shares. The comapny reported positive topline data at 36 weeks from the Phase II ALPACAR-360 study evaluating zerlasiran in patients with high Lp(a) levels who are at high risk for atherosclerotic cardiovascular disease events, the analyst tells investors in a research note. The firm believes the data for zerlasiran in this indication is encouraging thus far, and appears to be competitive with olpasiran.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLN:
- Silence Therapeutics announces ALPACAR-360 met primary endpoint
- SLN Earnings this Week: How Will it Perform?
- Silence Therapeutics to receive $10M from AstraZeneca following trial initiation
- UPS downgraded, Stryker upgraded: Wall Street’s top analyst calls
- Silence Therapeutics initiated with an Outperform at BMO Capital